JO3407B1 - مركبات رباعي هيدرو بيرازولو بيريميدين - Google Patents

مركبات رباعي هيدرو بيرازولو بيريميدين

Info

Publication number
JO3407B1
JO3407B1 JOP/2013/0166A JOP20130166A JO3407B1 JO 3407 B1 JO3407 B1 JO 3407B1 JO P20130166 A JOP20130166 A JO P20130166A JO 3407 B1 JO3407 B1 JO 3407B1
Authority
JO
Jordan
Prior art keywords
tetrahydropyrazolopyrimidine
compounds
tetrahydropyrazolopyrimidine compounds
sle
toll
Prior art date
Application number
JOP/2013/0166A
Other languages
English (en)
Inventor
Carlson Eric
D Hawkins Lynn
Narayan Sridhar
Ishizaka Sally
Satoh Takashi
Boivin Roch
Endo Atsushi
Hansen Hans
Mackey Matthew
Schiller Shawn
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of JO3407B1 publication Critical patent/JO3407B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

يتعلق الاختراع الحالي بمركبات تتراهيدرو بيرازولو بيريميدين والتي تعمل كمضادات أو مثبطات للمستقبلات البروتينية المنشطة للمناعة 7 و/أو 8، واستخدامها في تركيبات صيدلانية فعالة لعلاج الذئبة الحمامية المجموعية (<span dir="LTR">SLE</span>) والتهاب الكلية الذئبي.
JOP/2013/0166A 2012-05-31 2013-05-30 مركبات رباعي هيدرو بيرازولو بيريميدين JO3407B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261654023P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
JO3407B1 true JO3407B1 (ar) 2019-10-20

Family

ID=48626649

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0166A JO3407B1 (ar) 2012-05-31 2013-05-30 مركبات رباعي هيدرو بيرازولو بيريميدين

Country Status (34)

Country Link
US (5) US9126999B2 (ar)
EP (1) EP2855476B1 (ar)
JP (2) JP6285918B2 (ar)
KR (2) KR102268155B1 (ar)
CN (2) CN104507939B (ar)
AR (1) AR091236A1 (ar)
AU (2) AU2013267204B8 (ar)
BR (1) BR112014030060B1 (ar)
CA (1) CA2874445C (ar)
CL (1) CL2014003278A1 (ar)
CY (1) CY1122692T1 (ar)
DK (1) DK2855476T3 (ar)
ES (1) ES2709119T3 (ar)
HK (1) HK1203498A1 (ar)
HR (1) HRP20181889T1 (ar)
HU (1) HUE040562T2 (ar)
IL (2) IL268013B1 (ar)
JO (1) JO3407B1 (ar)
LT (1) LT2855476T (ar)
MX (1) MX368455B (ar)
MY (1) MY172926A (ar)
NZ (1) NZ703459A (ar)
PE (2) PE20190973A1 (ar)
PH (2) PH12014502660A1 (ar)
PL (1) PL2855476T3 (ar)
PT (1) PT2855476T (ar)
RS (1) RS57977B1 (ar)
RU (2) RU2733959C2 (ar)
SG (1) SG11201407890VA (ar)
SI (1) SI2855476T1 (ar)
TW (1) TWI572606B (ar)
UA (1) UA113440C2 (ar)
WO (1) WO2013181579A2 (ar)
ZA (1) ZA201409273B (ar)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
CN105636945B (zh) 2013-10-14 2017-11-17 卫材R&D管理有限公司 选择性取代的喹啉化合物
SI3057964T1 (sl) 2013-10-14 2020-03-31 Eisai R&D Management Co., Ltd. Selektivno substituirane spojine kinolina
EP3080124A1 (en) * 2013-12-13 2016-10-19 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
AU2015238298B2 (en) * 2014-03-27 2019-04-18 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
TR201909606T4 (tr) 2014-07-31 2019-07-22 Basf Se Pi̇razollari hazirlamak i̇çi̇n i̇şlem
US9938100B2 (en) 2014-12-30 2018-04-10 Kodak Alaris Inc. System and method for metallic object detection in a media transport system
KR20230145498A (ko) 2015-05-11 2023-10-17 바스프 에스이 4-아미노-피리다진의 제조 방법
AU2015401326B2 (en) * 2015-07-03 2018-07-26 China Agricultural University Benzylhydrazone compounds and preparation method and application thereof
US10975036B2 (en) * 2016-02-02 2021-04-13 Basf Se Catalytic hydrogenation process for preparing pyrazoles
CN107174585A (zh) * 2016-03-10 2017-09-19 兰州大学 可用作雄激素受体拮抗剂的吡啶并咪唑类化合物的新用途
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3031675A1 (en) * 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
CN109790126A (zh) * 2016-08-02 2019-05-21 索尔维公司 用于制造吡唑甲酸及衍生物的肼基化合物的制造、肼基化合物及其用途
CN109641899B (zh) * 2016-09-09 2022-07-22 诺华股份有限公司 作为内体Toll样受体抑制剂的化合物及组合物
CN109923108B (zh) * 2016-09-09 2022-04-29 百时美施贵宝公司 吡啶基取代的吲哚化合物
WO2018210298A1 (zh) * 2017-05-18 2018-11-22 江苏恒瑞医药股份有限公司 杂芳基并吡唑类衍生物、其制备方法及其在医药上的应用
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
CA3085333A1 (en) * 2017-12-15 2019-06-20 Bristol-Myers Squibb Company Substituted indole ether compounds
EA202091484A1 (ru) * 2017-12-18 2021-03-25 Бристол-Маерс Сквибб Компани 4-азаиндольные соединения
SG11202005696YA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Substituted indole compounds useful as tlr inhibitors
JP7313354B2 (ja) * 2017-12-19 2023-07-24 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物
WO2019126082A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
CN111511744B (zh) 2017-12-20 2023-09-22 百时美施贵宝公司 二氮杂吲哚化合物
EP3728218B1 (en) 2017-12-20 2021-12-01 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
EP3728188B1 (en) 2017-12-20 2023-10-11 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
JP2021506879A (ja) * 2017-12-22 2021-02-22 ソルヴェイ（ソシエテ アノニム） ピラゾールカルボン酸誘導体及びその前駆体の製造のための方法
JP2021507889A (ja) 2017-12-22 2021-02-25 ノバルティス アーゲー ピラゾロピペリジン誘導体の新規な使用
WO2019235553A1 (ja) * 2018-06-07 2019-12-12 第一三共株式会社 アゼチジン誘導体及びそのプロドラッグ
CN112654620B (zh) * 2018-09-06 2023-08-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的新型吡唑并吡啶化合物
US20210300924A1 (en) * 2018-11-09 2021-09-30 Hoffmann-La Roche Inc. 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus
CN113423708A (zh) * 2019-02-07 2021-09-21 百济神州有限公司 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物
EP4008720A4 (en) * 2019-08-02 2023-08-02 BeiGene, Ltd. IMIDAZO [2,1-F][1,2,4] TRIAZINE-4-AMINE DERIVATIVES AS A TLR8 AGONIST
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
US20230097700A1 (en) * 2019-12-06 2023-03-30 Daiichi Sankyo Company, Limited Azetidine sulfonamide compound
CA3214808A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Thienopyrrole compounds

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3116230B2 (ja) 1989-02-15 2000-12-11 武田薬品工業株式会社 三環式縮合ピリミジン誘導体
JPH04133055A (ja) 1990-09-25 1992-05-07 Konica Corp 色再現性の改良されたハロゲン化銀カラー写真感光材料
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
FR2733749B1 (fr) 1995-05-05 1997-06-13 Oreal Compositions pour la teinture des fibres keratiniques contenant des diamino pyrazoles, procede de teinture, nouveaux diamino pyrazoles et leur procede de preparation
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
RU2003120070A (ru) 2000-12-06 2004-12-27 Авентис Фармаа Дойчланд Гмбх (De) Производные гуанидина и амидина в качестве ингибиторов фактора ха
WO2002072585A2 (de) * 2001-03-14 2002-09-19 Grünenthal GmbH Substituierte pyrazolo- und thiazolopyrimidine als analgetika
BR0309281A (pt) 2002-04-26 2005-02-22 Pfizer Prod Inc Triaril-oxi-espiro-pirimidino-2,4,6-trionas inibidoras de metaloproteinases
DE10221100C1 (de) 2002-05-03 2003-06-05 Neuhaus Elektronik Gmbh Elektrisch leitfähige Dichtung sowie Verfahren und Vorrichtung zu deren Herstellung
JP2003327860A (ja) 2002-05-09 2003-11-19 Konica Minolta Holdings Inc 着色組成物、着色微粒子分散物、インクジェット用インク、インクジェット記録方法
EP1534707B9 (en) 2002-06-19 2008-11-26 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
JP4133055B2 (ja) 2002-07-11 2008-08-13 株式会社イトーキ 移載機構を備えた自動倉庫
ZA200500782B (en) * 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
PL382706A1 (pl) 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
CA2523743A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
CN1805928A (zh) 2003-06-12 2006-07-19 麦克公司 有丝分裂驱动蛋白抑制剂的前体药物
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
EP1648437A2 (en) 2003-07-01 2006-04-26 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
FR2865208B1 (fr) 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
US7279232B2 (en) 2004-01-26 2007-10-09 Universal Display Corporation Electroluminescent stability
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
BRPI0510639A (pt) 2004-05-04 2007-11-13 Acadia Pharm Inc composto ou um sal ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratar ou prevenir distúrbios, de terapia de reposição hormonal, de abaixar nìveis de colesterol, triglicerìdeos ou ldl, de tratar cognição prejudicada ou prover neuroproteção, de prevenir concepção, de modular ou agonizar especificamente um ou mais receptores de estrogênio e, uso de um composto
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
CA2583710A1 (en) 2004-10-12 2006-04-27 Decode Genetics, Inc. Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
US20060122222A1 (en) 2004-11-18 2006-06-08 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
WO2006057448A1 (ja) 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体
AU2006206274A1 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
EP1877054A2 (en) 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
JPWO2006129587A1 (ja) 2005-05-30 2009-01-08 株式会社ジーンケア研究所 ピラゾロン誘導体を含有する医薬組成物
JPWO2006129583A1 (ja) 2005-05-30 2009-01-08 株式会社ジーンケア研究所 ピラゾロン誘導体
JP2008546643A (ja) 2005-06-06 2008-12-25 スミスクライン ビーチャム コーポレーション ４−置換アリールアミン誘導体および医薬組成物におけるその使用
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
AU2006285599A1 (en) 2005-09-01 2007-03-08 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2007087283A2 (en) 2006-01-23 2007-08-02 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JPWO2007102531A1 (ja) 2006-03-08 2009-07-23 武田薬品工業株式会社 併用薬
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
US8853244B2 (en) 2006-05-23 2014-10-07 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009538305A (ja) 2006-05-23 2009-11-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
AU2007257841A1 (en) 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
KR101172936B1 (ko) 2006-07-14 2012-08-16 노파르티스 아게 Ａｌｋ-5 억제제로서의 피리미딘 유도체
ATE494289T1 (de) * 2006-08-04 2011-01-15 Merz Pharma Gmbh & Co Kgaa Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
WO2008033894A2 (en) 2006-09-14 2008-03-20 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008094992A2 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
CA2677296A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
WO2009035671A1 (en) 2007-09-12 2009-03-19 Janssen Pharmaceutica N.V. Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
AU2007360955A1 (en) 2007-11-15 2009-05-22 Eisai R & D Management Co., Ltd. Enantiomerically enriched imidazoazepinone compounds
EP2280766A1 (en) * 2007-12-11 2011-02-09 CytoPathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
US8338392B2 (en) 2008-02-20 2012-12-25 The Wistar Institute MicroRNA modulators and method for identifying and using the same
US20120010177A1 (en) 2008-02-20 2012-01-12 The Wistar Institute / North Carolina State University MicroRNA Modulators and Method for Identifying And Using The Same
WO2009111207A1 (en) 2008-03-04 2009-09-11 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US9066951B2 (en) 2008-05-29 2015-06-30 Wisconsin Alumni Research Foundation Drugs to treat HPV infection
US20110144056A1 (en) 2008-06-11 2011-06-16 Lin Linus S Pyrazole derivatives useful as inhibitors of faah
US8455528B2 (en) 2008-06-11 2013-06-04 Merck Sharp & Dohme Corp. Imidazole derivatives useful as inhibitors of FAAH
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
WO2009153721A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
US8263642B2 (en) 2008-06-25 2012-09-11 Vanderbilt University Antimicrobial compounds and methods of use thereof
JP5433691B2 (ja) 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
EP2303876B1 (en) 2008-06-25 2014-03-19 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
ES2463765T3 (es) 2008-08-04 2014-05-29 Merck Sharp & Dohme Corp. Derivados de oxazol útiles como inhibidores de la AHAG
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
ES2710701T3 (es) 2008-09-24 2019-04-26 Basf Se Compuestos de pirazol para el control de plagas de invertebrados
WO2010096115A1 (en) * 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
CA2741537A1 (en) 2008-11-07 2010-05-14 Wyeth Llc Quinoxaline-based lxr modulators
JP5630868B2 (ja) 2009-01-19 2014-11-26 第一三共株式会社 ヘテロ原子を有する環状化合物
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2010101964A2 (en) 2009-03-02 2010-09-10 Stemsynergy Therapeutics, Inc Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20120141483A1 (en) 2009-06-04 2012-06-07 Mary Katherine Delmedico Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AR078887A1 (es) 2009-11-06 2011-12-07 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
FR2953837B1 (fr) 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
WO2011079000A1 (en) 2009-12-22 2011-06-30 Schering Corporation DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b]PURIN-4(5H)-ONE AND METHODS OF USE THEREOF
US8981084B2 (en) 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
KR20120123691A (ko) 2010-01-28 2012-11-09 머크 샤프 앤드 돔 코포레이션 통증 및 기타의 적응증의 치료를 위한 제약 조성물
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
EP2371219A1 (en) 2010-04-01 2011-10-05 Basf Se Herbicidal acylhydrazides
ES2698048T3 (es) 2010-04-05 2019-01-30 Fosun Orinove Pharmatech Inc Inhibidores de IRE-1
CA2794724A1 (en) 2010-04-22 2011-10-27 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of faah
CA2811989A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Diarylpyridine anti-viral compounds
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
CN102048738A (zh) 2010-12-08 2011-05-11 辽宁利锋科技开发有限公司 含有环嘧耐平药用复合物的药物组合物制剂
WO2013019561A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
PT2736887T (pt) 2011-07-29 2018-01-15 Karyopharm Therapeutics Inc Modeladores de transporte nuclear contendo hidrazida e utilizações dos mesmos
JP2013159564A (ja) * 2012-02-02 2013-08-19 Kowa Co ピラゾロピリミジン−７−アミン誘導体を有効成分とするｔｌｒ９阻害剤
WO2013122823A1 (en) 2012-02-13 2013-08-22 Bristol-Myers Squibb Company Enediyne compounds, conjugates thereof, and uses and methods therefor
UY34832A (es) 2012-05-31 2013-12-31 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين

Also Published As

Publication number Publication date
AU2013267204A1 (en) 2015-01-29
WO2013181579A2 (en) 2013-12-05
JP2018087221A (ja) 2018-06-07
CN104507939A (zh) 2015-04-08
EP2855476A2 (en) 2015-04-08
UA113440C2 (xx) 2017-01-25
US10640500B2 (en) 2020-05-05
AU2017204586A1 (en) 2017-07-27
PH12019500522A1 (en) 2020-11-04
CN107344941B (zh) 2020-04-21
ES2709119T3 (es) 2019-04-15
AU2013267204A8 (en) 2017-04-13
AR091236A1 (es) 2015-01-21
JP6285918B2 (ja) 2018-02-28
NZ703459A (en) 2016-09-30
PT2855476T (pt) 2018-12-03
KR102403007B1 (ko) 2022-05-31
US9126999B2 (en) 2015-09-08
RU2018146532A3 (ar) 2019-06-21
IL235986B (en) 2019-11-28
AU2013267204B2 (en) 2017-04-06
CN107344941A (zh) 2017-11-14
IL268013A (en) 2019-09-26
PE20150220A1 (es) 2015-02-14
LT2855476T (lt) 2019-01-10
CA2874445A1 (en) 2013-12-05
JP6619829B2 (ja) 2019-12-11
TWI572606B (zh) 2017-03-01
US11130758B2 (en) 2021-09-28
US20180273532A1 (en) 2018-09-27
SI2855476T1 (sl) 2018-12-31
TW201402575A (zh) 2014-01-16
HRP20181889T1 (hr) 2019-01-11
CL2014003278A1 (es) 2015-06-12
CN104507939B (zh) 2017-07-25
AU2013267204B8 (en) 2017-04-13
AU2017204586B2 (en) 2018-11-08
RU2014154397A (ru) 2016-07-27
EP2855476B1 (en) 2018-09-05
RU2677291C2 (ru) 2019-01-16
BR112014030060A2 (pt) 2017-09-12
PH12014502660B1 (en) 2015-01-21
RU2733959C2 (ru) 2020-10-08
ZA201409273B (en) 2016-05-25
PH12014502660A1 (en) 2015-01-21
KR102268155B1 (ko) 2021-06-24
US9850242B2 (en) 2017-12-26
RU2018146532A (ru) 2019-01-31
WO2013181579A3 (en) 2014-03-27
RS57977B1 (sr) 2019-01-31
US20130324547A1 (en) 2013-12-05
CY1122692T1 (el) 2020-07-31
MX368455B (es) 2019-10-03
HK1203498A1 (en) 2015-10-30
PE20190973A1 (es) 2019-07-09
IL235986A0 (en) 2015-02-01
HUE040562T2 (hu) 2019-03-28
US9446046B2 (en) 2016-09-20
KR20210076210A (ko) 2021-06-23
MY172926A (en) 2019-12-14
US20200347050A1 (en) 2020-11-05
US20160030430A1 (en) 2016-02-04
BR112014030060B1 (pt) 2022-05-31
CA2874445C (en) 2022-06-21
US20160339032A1 (en) 2016-11-24
JP2015523981A (ja) 2015-08-20
KR20150016366A (ko) 2015-02-11
MX2014014497A (es) 2015-06-02
PL2855476T3 (pl) 2019-02-28
SG11201407890VA (en) 2014-12-30
IL268013B1 (en) 2024-01-01
DK2855476T3 (en) 2018-12-17

Similar Documents

Publication Publication Date Title
PH12019500522A1 (en) Tetrahydropyrazolopyrimidine compounds
MX2019005192A (es) Compuestos de quinolina selectivamente sustituida.
MX2016004629A (es) Compuestos de quinolina selectivamente sustituidos.
PH12018501463A1 (en) Pyrimidinyl tyrosine kinase inhibitors
MY179781A (en) Biaryl inhibitors of bruton&#39;s tyrosine kinase
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
IN2015DN00127A (ar)
IN2014DN10386A (ar)
PH12015502141A1 (en) Substituted xanthines and methods of use thereof
IL242545B (en) Compositions and methods for administering hydrophobic active substances
IN2013MU03641A (ar)
MX2016007947A (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con caracteristicas melancolicas.
MY168958A (en) Intermediates and processes for preparing compounds